Pharmacy benefit companies are strong proponents of a highly functioning biosimilar market. Bringing more biosimilars to market, over time, will allow PBMs to more effectively leverage competition to reduce drug costs for health plan sponsors and patients. As biosimilar competition
Blumenthal-Cornyn Legislation Would Encourage More Generic and Biosimilar Competition in the Prescription Drug Market to Help Lower Costs for Patients (Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) released the following statement today following the reintroduction of the “Affordable
Fact: Employers are under no obligation to hire pharmacy benefit companies, but a vast majority of employers work with pharmacy benefit companies. Recent findings from the PricewaterhouseCoopers (PwC) 2021 “Health and Well-being Touchstone Survey” of 368 companies explains why employers,
In case you missed it, Katie Payne, senior vice president for strategic communications for the Pharmaceutical Care Management Association (PCMA), discusses how the BIO International Convention happening this week in Boston, MA misses the critical opportunity to address the root
Pharmacy benefit companies push big drug companies for price concessions through rebates. 99.6 percent of rebates get passed directly to Medicare Part D plans, and 91 percent to other health plan sponsors, like employers and unions, who use those savings
(Washington, D.C.) — Pharmaceutical Care Management Association (PCMA) President and CEO JC Scott released the following statement on a new advertising campaign against Section 306 in S. 1895, the “Lower Health Care Costs Act:”
©2024 PCMA. All Rights Reserved.
